Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Loren Michel(Washington University in St. Louis), Douglas R. Adkins(Washington University in St. Louis), Se‐Eun Chun(Seoul National University), András Schaffer, Kathryn Trinkaus(Washington University in St. Louis), Wooin Lee(Seoul National University), Anthony Robinson, Jessica Ley(Washington University in St. Louis), Tanya M. Wildes(University of Nebraska Medical Center), James S. Lewis(Vanderbilt University Medical Center)
Cited by 88
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632